Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of APL018 in patients with CHD
A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
Study Start Date
Primary Completion Date
Resource links provided by the National Library of Medicine
Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD) [ Time Frame: throughout the study ]
Secondary Outcome Measures
Pharmacokinetic/pharmacodynamic relationship after a single and 7 daily infusions in CHD patients [ Time Frame: throughout the study ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female healthy volunteers (ages 18-55 years) and patients with CHD (ages 18 to 75 years) on stable statin therapy for at least 8 weeks, with normal liver and kidney function.
Women who are post-menopausal, surgically sterile, or practicing effective contraception. Additional birth control details to be provided at screening.
Body mass index (BMI) must be within the range of 20 to 35 for CHD patients or CHD equivalents.
Myocardial infarction (MI), angina, revascularization (e.g. CABG, stent) at least 6 months prior to inclusion
symptomatic carotid artery disease (e.g. transient ischemic attack or stroke of carotid origin) or peripheral artery disease or abdominal aortic aneurysm or Diabetes Mellitus (HbA1c ≤9)
20% 10 year risk of CHD (Framingham point score: ≥16 (men), ≥23 (women))
Other clinical forms of atherosclerotic disease including >50 percent stenosis on angiography or ultrasound
Male subjects, when sexually active, using one form of highly effective contraception (e.g. condom)
Exclusion Criteria for both healthy volunteers and patients:
Smokers (use of tobacco products in the previous 3 months). Smokers who report cigarette use of more then 10 cigarette per day or have a urinary cotinine level greater then 500 ng/ml.
Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Significant illness within two weeks prior to dosing.
Significant illness within two weeks prior to dosing.
A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome.
History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug or any allergic reaction to prior receipt of protein therapies or vaccines.
Presence of NYHA Class III or IV CHF or unstable angina pectoris.
MI or within angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to dosing.
Use of certain medications prohibited by the protocol.
Uncontrolled diabetes (HbA1c > 9).
Uncontrolled hypertension (Systolic BP >160 mm Hg and/or Diastolic BP >100 mmHg on two consecutive measurements).
Liver or kidney disease confirmed by abnormal lab values or function.
Serum creatine kinase CK (CPK) total > 2x.
CHD equivalent patients with a history of early positive exercise stress test.
Other protocol-defined inclusion/exclusion criteria may apply